Converthera Nad Plus Patch
NDC 85945-0001
Product Information
Converthera Nad Plus Patch is a UNAPPROVED DRUG OTHER-approved product labeled by Through Medical Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a patch for transdermal administration. This product entry covers the primary NDC 85945-0001 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 85945-0001?
What are the uses of this product?
What are Active Ingredients of this product?
- GLUTATHIONE 25 mg/U - A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
- NICOTINAMIDE ADENINE DINUCLEOTIDE 250 mg/U - A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NICOTINAMIDE ADENINE DINUCLEOTIDE (UNII: 0U46U6E8UK)
- NICOTINAMIDE ADENINE DINUCLEOTIDE (UNII: 0U46U6E8UK) (Active Moiety)
- GLUTATHIONE (UNII: GAN16C9B8O)
- GLUTATHIONE (UNII: GAN16C9B8O) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE (UNII: J2B2A4N98G)
- GLUTENIN (UNII: FX065C7O71)
* Please review the full disclaimer at the bottom of this page.